Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | INCB123667 |
| Synonyms | |
| Therapy Description |
INCB123667 selectively inhibits CDK2, potentially leading to decreased growth of CCNE-overexpressing tumors (European Journal of Cancer 174 (2022): S79). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| INCB123667 | INCB-123667|INCB 123667 | CDK2 Inhibitor 31 | INCB123667 selectively inhibits CDK2, potentially leading to decreased growth of CCNE-overexpressing tumors (European Journal of Cancer 174 (2022): S79). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05238922 | Phase I | INCB123667 | Study of INCB123667 in Subjects With Advanced Solid Tumors | Recruiting | USA | NLD | ITA | GBR | FRA | CHE | 2 |
| NCT07023627 | Phase II | INCB123667 | A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression | Recruiting | USA | GBR | ESP | CHE | BEL | AUS | 2 |